REG-4basebio Plc: 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine

4BasebioAnnouncement

21/03/2024 07:00

  21 March 2024

4basebio PLC

("4basebio" or the "Company")

4basebio announces key milestone with its client progressing into Phase I
clinical trials of an
mRNA vaccine manufactured from 4basebio’s opDNA™

Cambridge, UK, 21 March 2024 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform, today announces that the Company’s client, Helix
Nanotechnologies Inc. (“HelixNano”) has received HREC approval to progress
into a Phase I clinical trial in Australia with HN-0001, an mRNA vaccine
generated from 4basebio’s synthetic DNA, opDNA™.  

4basebio will continue to support HelixNano with the manufacture of GMP
synthetic DNA planned for later in 2024.

Dr Amy Walker, VP of Research and Business Development at the Company,
commented: "It’s been a pleasure to work with such an innovative company on
their journey to the clinic and we are delighted to see an mRNA vaccine
manufactured using 4basebio DNA progressing into patients; this represents
another significant milestone for the company.”

“4basebio has several clients requiring GMP grade DNA and progressing
towards clinical trials; we are of course very pleased to be supporting our
clients in their clinical programs.”

Dr Marianna Keaveney, Director of Clinical Product Development at HelixNano,
commented: “It's an incredible milestone for HelixNano to secure approval
for our first clinical trial, and we would not have been able to develop this
drug product without the commitment of the 4basebio team. We look forward to
continuing our work together.”

For further enquiries, please contact:

 4basebio PLC Heikki Lanckriet                                                          +44 (0)12 2396 7943  
 Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson               +44 (0)20 7213 0880  
 Broker    Cavendish Geoff Nash / Charlie Beeson / Nigel Birks                          +44 (0)20 7220 0500  
 Lionsgate Communications (Media Enquiries) Jonathan Charles                            +44 (0)77 91892509   

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients. The company is offering GMP compliant DNA starting
materials suitable for use in AAV viral vector production as well as mRNA
vaccine and therapeutics production.

About Helix Nanotechnologies Inc.
Helix Nanotechnologies Inc. is a biotechnology company headquartered in
Boston, MA. HelixNano is focused on building a universal interface to the
immune system to tap into the innate power of the human body to fight disease.
HelixNano is currently developing mRNA-based therapeutics in infectious
disease, oncology, and other indications.
 

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved